Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer

Background: Radiotherapy is one of the primary therapies for localized prostatic carcinoma. Therefore, there is an emerging need to sensitize prostatic cancer cells to chemotherapy/radiotherapy. Modified citrus pectin (MCP) is an effective inhibitor of galectin-3 (Gal-3), which is correlated with tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Conti, Sefora, Vexler, Akiva, Hagoel, Lior, Kalich-Philosoph, Lital, Corn, Benjamin W., Honig, Nir, Shtraus, Natan, Meir, Yaron, Ron, Ilan, Eliaz, Isaac, Lev-Ari, Shahar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247563/
https://www.ncbi.nlm.nih.gov/pubmed/30043669
http://dx.doi.org/10.1177/1534735418790382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247563/
https://www.ncbi.nlm.nih.gov/pubmed/30043669
http://dx.doi.org/10.1177/1534735418790382

Ejemplares similares